{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:01:44Z","timestamp":1765382504990,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["ID#63238211"],"award-info":[{"award-number":["ID#63238211"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40120-024-00621-w","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T11:01:56Z","timestamp":1715338916000},"page":"1069-1080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, Tolerability, and Outcomes of Tafamidis for the Treatment of Acquired Amyloid Neuropathy in Domino Liver Transplant Recipients"],"prefix":"10.1007","volume":"13","author":[{"given":"Velina","family":"Nedkova-Hristova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Donadeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Baliellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Gonz\u00e1lez-Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Llad\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Gonz\u00e1lez-Vilatarsana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"V\u00e9lez-Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mios\u00e9s Morales","family":"de la Prida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1170-2676","authenticated-orcid":false,"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama CT. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15:387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4.","journal-title":"Nat Rev Neurol"},{"key":"621_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113\u20136. https:\/\/doi.org\/10.1016\/0140-6736(93)93127-M.","journal-title":"Lancet"},{"issue":"4","key":"621_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.trre.2011.04.002","volume":"25","author":"W Kitchens","year":"2011","unstructured":"Kitchens W. Domino liver transplantation: indications, techniques, and outcomes. Transplant Rev. 2011;25(4):167\u201377. https:\/\/doi.org\/10.1016\/j.trre.2011.04.002.","journal-title":"Transplant Rev"},{"issue":"3","key":"621_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4254\/wjh.v9.i3.126","volume":"9","author":"D Mnatsakanova","year":"2017","unstructured":"Mnatsakanova D, \u017divkovi\u0107 S. Iatrogenic amyloid polyneuropathy after domino liver transplantation. World J Hepatol. 2017;9(3):126\u201330. https:\/\/doi.org\/10.4254\/wjh.v9.i3.126.","journal-title":"World J Hepatol"},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3109\/13506129.2014.885894","volume":"21","author":"MM Abdelfatah","year":"2014","unstructured":"Abdelfatah MM, Hayman SR, Gertz MA. Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy. Amyloid. 2014;21:136\u20137. https:\/\/doi.org\/10.3109\/13506129.2014.885894.","journal-title":"Amyloid"},{"issue":"2","key":"621_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/lt.21073","volume":"13","author":"B-G Ericzon","year":"2007","unstructured":"Ericzon B-G. Domino transplantation using livers from patients with familial amyloidotic polyneuropathy: should we halt? Liver Transpl. 2007;13(2):185\u20137. https:\/\/doi.org\/10.1002\/lt.21073.","journal-title":"Liver Transpl"},{"issue":"2","key":"621_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/lt.20954","volume":"13","author":"Y Takei","year":"2007","unstructured":"Takei Y, Gono T, Yazaki M, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl. 2007;13(2):215\u20138.","journal-title":"Liver Transpl"},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1432-2277.2007.00516.x","volume":"20","author":"S Yamamoto","year":"2007","unstructured":"Yamamoto S, Wilczek HE, Iwata T, et al. Long-term consequences of domino liver transplantation using familial amyloidotic polyneuropathy grafts. Transpl Int. 2007;20:926\u201333. https:\/\/doi.org\/10.1111\/j.1432-2277.2007.00516.x.","journal-title":"Transpl Int"},{"issue":"suppl 13","key":"621_CR9","first-page":"16","volume":"16","author":"D Adams","year":"2009","unstructured":"Adams D, Lacroix C, Antonini T, et al. Risk of developing de novo amyloid deposits and induced polyneuropathy in FAP domino liver recipients [abstract]. Eur J Neurol. 2009;16(suppl 13):16\u201354.","journal-title":"Eur J Neurol"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/lt.21928","volume":"16","author":"AP Barreiros","year":"2010","unstructured":"Barreiros AP, Geber C, Birklein F, Galle PR, Otto G. Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. Liver Transpl. 2010;16:109. https:\/\/doi.org\/10.1002\/lt.21928.","journal-title":"Liver Transpl"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/lt.22174","volume":"16","author":"L Llad\u00f3","year":"2010","unstructured":"Llad\u00f3 L, Baliellas C, Casasnovas C, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl. 2010;16:1386\u201392. https:\/\/doi.org\/10.1002\/lt.22174.","journal-title":"Liver Transpl"},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijsu.2020.03.017","volume":"82S","author":"H Marques","year":"2020","unstructured":"Marques H, Barros I, Li J, et al. Current update in domino liver transplantation. Int J Surg. 2020;82S:163\u20138. https:\/\/doi.org\/10.1016\/j.ijsu.2020.03.017.","journal-title":"Int J Surg"},{"issue":"24","key":"621_CR13","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658\u201367. https:\/\/doi.org\/10.1001\/jama.2013.283815.","journal-title":"JAMA"},{"issue":"8","key":"621_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, da Silva AM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392. https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1.","journal-title":"Neurology"},{"issue":"1","key":"621_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793.","journal-title":"N Engl J Med"},{"issue":"1","key":"621_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"N Engl J Med"},{"key":"621_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10454","author":"V Nedkova-Hristova","year":"2022","unstructured":"Nedkova-Hristova V, Baliellas C, Gonz\u00e1lez-Castello J, et al. Treatment with diflunisal in domino liver transplant recipients with acquired amyloid neuropathy. Transpl Int. 2022. https:\/\/doi.org\/10.3389\/ti.2022.10454.","journal-title":"Transpl Int"},{"issue":"17","key":"621_CR18","doi-asserted-by":"publisher","first-page":"e1587","DOI":"10.1212\/WNL.000000000000836","volume":"93","author":"Y Misumi","year":"2019","unstructured":"Misumi Y, Ueda M, Masuda T, et al. Characteristics of acquired transthyretin amyloidosis. Neurology. 2019;93(17):e1587\u201396. https:\/\/doi.org\/10.1212\/WNL.000000000000836.","journal-title":"Neurology"},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/cjp2.36","volume":"2","author":"T Yoshinaga","year":"2016","unstructured":"Yoshinaga T, Yazaki M, Sekijima Y, et al. The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation. J Pathol Clin Res. 2016;2:72\u20139. https:\/\/doi.org\/10.1002\/cjp2.36.","journal-title":"J Pathol Clin Res"},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.2169\/internalmedicine.8434-16","volume":"56","author":"M Matsushima","year":"2017","unstructured":"Matsushima M, Yabe I, Tsuda M, Sakakibara M, Shimamura T, Sasaki H. Amyloid polyneuropathy and myocardial amyloidosis 10 years after domino liver transplantation from a patient with a transthyretin Ser50Arg mutation. Intern Med. 2017;56:3231\u20135. https:\/\/doi.org\/10.2169\/internalmedicine.8434-16.","journal-title":"Intern Med"},{"key":"621_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14822","author":"K Tsamis","year":"2022","unstructured":"Tsamis K, Mytilinaios D, Heneghan M, Gillmore J, et al. Treatment of acquired transthyretin amyloidosis in domino liver transplantation. Clin Transplant. 2022. https:\/\/doi.org\/10.1111\/ctr.14822.","journal-title":"Clin Transplant"},{"key":"621_CR22","unstructured":"Agreement of the Pharmacotherapeutic Committee for the Comprehensive Public Use Health System of Catalonia (CFT-SISCAT) of CatSalut on the use of tafamidis, inotersen and patisiran for the treatment of polyneuropathy due to hereditary transthyretin amyloidosis. https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/_compartits\/amiloidosi-polineuropatia\/acord-CFT-SISCAT-tafamidis-inotersen-patisiran-ATTRh.pdf. Accessed Mar 2024."},{"issue":"7","key":"621_CR23","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1111\/ajt.12285","volume":"13","author":"O Bestard","year":"2013","unstructured":"Bestard O, Crespo E, Stein M, et al. Cross-validation of IFN-\u03b3 Elispot assay for measuring alloreactive memory\/effector T cell responses in renal transplant recipients. Am J Transplant. 2013;13(7):1880\u201390. https:\/\/doi.org\/10.1111\/ajt.12285.","journal-title":"Am J Transplant"},{"issue":"11","key":"621_CR24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/cid\/ciu589","volume":"59","author":"M L\u00facia","year":"2014","unstructured":"L\u00facia M, Crespo E, Melilli E, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis. 2014;59(11):1537\u201345. https:\/\/doi.org\/10.1093\/cid\/ciu589.","journal-title":"Clin Infect Dis"},{"key":"621_CR25","unstructured":"Familial Amyloidotic Polyneuropathy World Transplant Registry and Domino Liver Transplant Registry. www.fapwtr.org. Accessed Mar 2024."},{"issue":"12","key":"621_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126526","volume":"4","author":"C Monteiro","year":"2019","unstructured":"Monteiro C, Mesgazardeh J, Anselmo J, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4(12): e126526. https:\/\/doi.org\/10.1172\/jci.insight.126526.","journal-title":"JCI Insight"},{"issue":"2","key":"621_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"GF Plant\u00e9-Bordeneuve","year":"2017","unstructured":"Plant\u00e9-Bordeneuve GF, Salhi H, Nordine T, Ayache S, Corvoisier P, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. Neurology. 2017;264(2):268\u201376. https:\/\/doi.org\/10.1007\/s00415-016-8337-3.","journal-title":"Neurology"},{"issue":"2","key":"621_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T, Garcia-Pavia P, Hanna M, Judge D, Merlini G, Gundapaneni B. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277\u201385. https:\/\/doi.org\/10.1002\/ejhf.2027.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"621_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/nat.2019.0829","volume":"30","author":"P Narayanan","year":"2020","unstructured":"Narayanan P, Curtis B, Shen L, et al. Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia. Nucleic Acid Ther. 2020;30(2):94\u2013103. https:\/\/doi.org\/10.1089\/nat.2019.0829.","journal-title":"Nucleic Acid Ther"},{"key":"621_CR30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.08.018","author":"S Law","year":"2022","unstructured":"Law S, Arnold J, Rauf M, et al. Focal segmental glomerulosclerosis complicating therapy with inotersen, an antisense oligonucleotide inhibitor: a case report. Am J Kidney Dis. 2022. https:\/\/doi.org\/10.1053\/j.ajkd.2022.08.018.","journal-title":"Am J Kidney Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00621-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00621-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00621-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:24:45Z","timestamp":1721629485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00621-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00621-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"3 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laura Doneu\u2019s funding: Predoctoral Contract for Health Research Training (PFIS) funded by Instituto de Salud Carlos III. Oriol Bestard\u00b4s funding: Competitive grant PI19\/01710 funded by Instituto de Salud Carlos III and co-fundede by European Union (ERDF\/ESF)\u2014A way to build Europe. RICORS (Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud) consortia (Intituto de Salud Carlos III).Competitive grant PI22\/01019 funded by Instituto de Salud Carlos III and co-fundede by European Union (ERDF\/ESF)\u2014A way to build Europe. Carmen Baliellas, Jos\u00e9 Gonz\u00e1lez-Costello, Laura Llad\u00f3 and Emma Gonz\u00e1lez-Vilatarsana has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Ethical approval was obtained by Ethics Committee for Drug Research of Bellvitge University Hospital and the Spanish Agency of Medicines and Medical Devices (reference number: EPA 020\/20; CCP-TAF-2020-01). All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all participants in the study for data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}